Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab for Refractory Antiphospholipid Syndrome (BLAST)
NCT05020782Phase 3Unknown
- Sponsor
- University of Turin
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
A Phase 3 trial of belimumab in antiphospholipid syndrome (APS), sponsored by University of Turin. Status: unknown.
02
Drugs
belimumab
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT05020782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020782.